Nine Diagnostics – February 12, 2025
Nine Diagnostics, a leader in AI-enabled nanosensor technology, has been selected to participate in the American Cancer Society’s BrightEdge Entrepreneurs Program, a highly selective initiative designed to accelerate promising and high impact potential oncology-focused startups. This selection marks another significant milestone for Nine Diagnostics as it continues to drive innovation in cancer treatment selection, dosing, optimization, and monitoring.
The BrightEdge Entrepreneurs Program is a highly competitive initiative that provides selected startups with access to top-tier mentorship, investment opportunities, and strategic industry connections. By integrating Nine Diagnostics into this prestigious network, BrightEdge will help to support the company’s potential to transform cancer diagnostics through advanced AI and novel nanosensor technology.
Through the program, Nine Diagnostics will benefit from expert guidance, direct engagement with oncology thought leaders, and opportunities to scale its technology in collaboration with leading institutions and investors. The company is poised to leverage these resources to further its mission of transforming early cancer detection and improving patient outcomes worldwide.
“Joining the BrightEdge Entrepreneurs Program is a tremendous opportunity for Nine Diagnostics,” said Freddy T. Nguyen, MD, PhD, co-founder of Nine Diagnostics. “This recognition validates our vision and the potential impact of our AI-enabled nanosensor technology. With the support of BrightEdge, we are positioned to accelerate our innovations and bring game-changing solutions to the fight against cancer.”
